These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The clinical impact of platelet glycoprotein IIb/IIIa receptor blockade in cardiovascular medicine. Mak KH; Tan AT; Chan C; Koh TH; Topol EJ Jpn Circ J; 1998 Apr; 62(4):233-43. PubMed ID: 9583455 [TBL] [Abstract][Full Text] [Related]
3. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Quinn MJ; Plow EF; Topol EJ Circulation; 2002 Jul; 106(3):379-85. PubMed ID: 12119257 [No Abstract] [Full Text] [Related]
4. Glycoprotein IIb/IIIa platelet receptor blockers: are they ready for prime time in patients with unstable coronary artery disease? Conti CR Clin Cardiol; 1999 Feb; 22(2):57-8. PubMed ID: 10068840 [No Abstract] [Full Text] [Related]
6. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. Stringer KA Ann Pharmacother; 1999 Jun; 33(6):712-22. PubMed ID: 10410186 [TBL] [Abstract][Full Text] [Related]
11. [Inhibitors of platelet receptors GP IIB/IIIA: a new therapeutic class and its promise in the treatment of acute coronary syndromes]. Yerna M; Legrand V; Kulbertus H Rev Med Liege; 1997 May; 52(5):329-35. PubMed ID: 9273634 [No Abstract] [Full Text] [Related]
12. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors. Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249 [TBL] [Abstract][Full Text] [Related]
13. Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists. Steinhubl SR Coron Artery Dis; 2003 Aug; 14(5):381-6. PubMed ID: 12878903 [No Abstract] [Full Text] [Related]
14. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173 [TBL] [Abstract][Full Text] [Related]
15. Basic and clinical aspects of platelet integrin alphaIIbbeta3 receptor antagonists in acute coronary syndromes. Goudevenos JA; Tselepis AD Curr Opin Investig Drugs; 2001 Feb; 2(2):244-9. PubMed ID: 11816838 [No Abstract] [Full Text] [Related]
16. Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study). Tamberella MR; Bhatt DL; Chew DP; Kereiakes DJ; Topol EJ; Steinhubl SR; Am J Cardiol; 2002 Jun; 89(12):1429-31. PubMed ID: 12062743 [No Abstract] [Full Text] [Related]
17. [Therapeutic inhibition of platelets in a acute coronary syndrome and in coronary intervention: mechanisms and clinical results]. Peter K; Nordt T; Bode C Z Kardiol; 2000; 89 Suppl 7():60-9. PubMed ID: 11098561 [TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Nannizzi-Alaimo L; Alves VL; Phillips DR Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789 [TBL] [Abstract][Full Text] [Related]
19. Safety of the use of IIb/IIIa receptor blockers with or without the use of other anticoagulants. Ferguson JJ; Lau TK Semin Interv Cardiol; 1999 Jun; 4(2):97-102. PubMed ID: 10473879 [No Abstract] [Full Text] [Related]
20. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function. Kereiakes DJ Rev Cardiovasc Med; 2006; 7 Suppl 4():S3-11. PubMed ID: 17224889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]